Acne vs Eczema — Clinical Trial Comparison
Acne
Oil gland inflammation and comedones
Eczema (Atopic Dermatitis)
Dry, itchy skin with immune dysregulation
Acne and eczema are the two most common skin conditions in the UK. Acne affects up to 95% of adolescents and many adults, driven by excess oil production and bacterial colonisation. Eczema (atopic dermatitis) is an inflammatory condition characterised by dry, intensely itchy skin. Their trial landscapes are very different — eczema has seen a revolution in biological treatments, while acne research is now entering its own biological era.
Key Differences at a Glance
| Feature | Acne | Eczema (Atopic Dermatitis) |
|---|---|---|
| Primary mechanism | Sebum overproduction + Cutibacterium acnes + follicular plugging + inflammation | Skin barrier dysfunction + Th2 immune activation + microbiome imbalance |
| UK prevalence | ~95% of adolescents; ~20% of adults | ~15–20% of children; ~2–10% of adults |
| Main locations | Face, chest, upper back | Cubital/popliteal fossae, hands, face (children), widespread |
| Key symptom | Spots (comedones, papules, pustules, cysts), oily skin | Dry skin, intense itching, red patches, weeping/crusting |
| Psychological impact | High — scarring, self-esteem, anxiety/depression | High — sleep disruption, itching, self-consciousness |
| NICE first-line treatment | Topical retinoids ± benzoyl peroxide; antibiotics; oral isotretinoin for severe | Emollients + topical corticosteroids; dupilumab for severe; JAK inhibitors |
Clinical Trial Availability
| Trial Aspect | Acne | Eczema |
|---|---|---|
| UK trials actively recruiting | 15–25 studies | 30–50 studies |
| Most common trial phase | Phase 2–3 | Phase 2–4 |
| Top interventions tested | Topical retinoids, antimicrobial peptides, anti-sebum agents, biologics (early), light therapy | JAK inhibitors, next-gen biologics, topical JAK, microbiome therapies, skin barrier repair |
| Biological treatments | Emerging (anti-IL-17, anti-sebum agents) | Established (dupilumab) + expanding (tralokinumab, lebrikizumab, JAK inhibitors) |
| Topical innovation | Clascoterone (first topical anti-androgen), novel retinoids | Topical JAK inhibitors (ruxolitinib, delgocitinib), microbiome creams |
| Device trials | Laser/light-based, photodynamic therapy | Phototherapy, wet wrap, wearable monitoring |
Exciting Emerging Treatments
Acne Trials
- Clascoterone (Winlevi) — first topical anti-androgen for acne, now approved and in further trials
- Anti-IL-17 biologics — borrowing from psoriasis success for severe inflammatory acne
- Antimicrobial peptides — targeting C. acnes without antibiotics
- Sebum-modulating agents — topical and systemic agents reducing oil production
- Microbiome-based therapies — bacterial transplantation and prebiotic approaches
- Low-dose isotretinoin protocols — minimising side effects while maintaining efficacy
Eczema Trials
- Lebrikizumab (anti-IL-13) — next-generation biologic with strong Phase 3 results
- Topical JAK inhibitors — ruxolitinib cream and delgocitinib for mild-moderate disease
- Microbiome therapies — Roseomonas mucosa and bacterial transplant approaches
- Skin barrier repair agents — novel filaggrin-boosting creams and ceramide technology
- Oral JAK inhibitors — abrocitinib and upadacitinib in new populations (children, hand eczema)
- Digital monitoring and AI diagnosis — smartphone-based severity tracking for trial endpoints
💡 Adult acne is on the rise — and it has different trial options
Adult acne (especially in women) is increasingly common and has different characteristics from teenage acne — more inflammatory, more along the jawline, often hormonally driven. Several UK trials specifically target adult female acne, testing hormonal therapies, anti-androgens, and novel topical agents. If you're over 25 with persistent acne, look specifically for adult acne trials rather than general acne studies.
Eligibility Differences
Acne Trial Criteria
- Acne severity grading (IGA score 2–4 for most drug trials)
- Lesion count requirements (inflammatory and non-inflammatory minimums)
- Face involvement usually required (some trials also include trunk)
- Prior treatment history matters — some trials require failure of standard treatments
- Women of childbearing age: pregnancy testing and contraception requirements (especially for retinoid trials)
Eczema Trial Criteria
- Confirmed atopic dermatitis diagnosis (Hanifin & Rajka or UK Working Party criteria)
- Severity scoring (EASI, SCORAD, IGA) — moderate-to-severe for biologic/JAK trials
- Body surface area involvement (typically ≥ 10% for systemic therapy trials)
- Failed or intolerant to topical treatments (for systemic therapy trials)
- Atopic history (personal or family) may be required for some studies